secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0001628280-22-011605
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 closes GeneDx acquisition; Stueland becomes CEO, Schadt shifts to President
--------------------------------------------------------------------------------

- Acquired GeneDx for $150M cash + 80M shares upfront; up to $150M in revenue-based milestones.
- Closed $200M PIPE at $4.00/share with institutional investors including Pfizer.
- Katherine Stueland appointed CEO; Eric Schadt becomes President & Chief R&D Officer.
- Board expanded to 11; Stueland and Richard Pfenniger elected as Class III directors.
- Authorized Class A common shares increased from 380M to 1B via charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000162828022011605/0001628280-22-011605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000162828022011605/smfr-20220429.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-011605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer